ArticleBlood advances2025

Siltuximab for chimeric antigen receptor T-cell therapy-related CRS and ICANS: a multicenter retrospective analysis.

Amneet Bajwa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.